Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HPD | P32754 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402800 | 1.00 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL26401575 | 0.87 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL24478646 | 0.85 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL30516693 | 0.85 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL3777362 | 0.85 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL2521491 | 0.85 | HPGD (0.52) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL28029191 | 0.85 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL26604443 | 0.83 | KMT2A (0.54) | ALDH1A1SMN1; SMN2KMT2AMEN1HPD | |
| SCHEMBL30662860 | 0.83 | KMT2A (0.54) | ALDH1A1SMN1; SMN2KMT2AMEN1HPD | |
| SCHEMBL8421994 | 0.82 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-115996912-A | Iminothiolanone inhibitors of ENPP1 | 沃拉斯查疗法公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4146344-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | Volastra Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | ALDH1A1 1567/4885SMN1; SMN2 820/4885KMT2A 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.